Goldstein et al. have assessed the incidence of upper gastrointestinal complications in patients treated with the COX-2-selective inhibitor, valdecoxib. The authors carried out a predefined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback